• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy

    5/13/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email

    Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1

    WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the publication of a new retrospective analysis of clinical data associating the use of the Titan SGS™ Stapler with reduced rates of post-operative GERD following robotic-assisted laparoscopic sleeve gastrectomy (LSG) compared with traditional multi-fire surgical staplers.1 The retrospective study comprised 257 patients who underwent robot-assisted sleeve gastrectomy using the Titan SGS™ Stapler or multiple fires of a traditional linear stapler between 2016 and 2023. All procedures included in the study were performed by a single surgeon.1 The study has been published online in Obesity Surgery.1

    Sleeve gastrectomy is the most common weight-loss surgery in the U.S.2 While the procedure is associated with a low rate of adverse events during and following surgery, a 2024 review of 109 studies found "a persistent concern for worsening and de novo GERD" after sleeve gastrectomy.3 Pouch shapes based on anatomical landmarks have previously been shown to help reduce the incidence of GERD4 but highly variable surgical techniques and multiple stapler fires yield inconsistent pouch anatomy.5 Consequently, one study found that bariatric surgeons have been able to achieve the ideal tubular sleeve anatomy less than 40% of the time, resulting in inconsistent patient outcomes, including GERD and nausea.5

    "Improving clinical outcomes for patients — including the development of post-operative GERD — may be important for wider adoption of bariatric surgery, which remains the most effective and durable obesity treatment," said Forrest Ringold, MD, FACS, SAGES, an expert in bariatric and robotic surgery at the Surgical Association of Mobile and senior researcher on the publication. "This study shows that GERD was less common in LSG procedures that used the Titan SGS™ Stapler. I believe this is because the 23cm single-fire Titan SGS™ Stapler is intentionally designed to enable more consistent and symmetrical sleeve anatomy and to provide reproducible pouch anatomies from patient to patient.6 This study adds to a growing body of evidence supporting the potentially enhanced perioperative benefits linked to the Titan SGS™ Stapler in sleeve gastrectomy."

    The Titan SGS™ Stapler is the first and only single-fire, surgical stapler designed and indicated specifically for sleeve gastrectomy pouch creation.6 As the only stapler to provide a 23cm staple line — the industry's longest continuous staple cutline —the Titan SGS™ Stapler is designed to provide an ideal tubular surgical sleeve anatomy that is a consistent shape, free of kinks, twists, or spirals, improving the potential to resolve GERD and nausea.4,7

    The publication reports retrospective observational data that at one-year post-procedure, significantly fewer patients in the Titan SGS™ Stapler cohort reported having GERD (7.1%) compared with the multi-fire cohort (26.4%) (p = 0.002) and significantly fewer patients in the Titan SGS™ Stapler cohort developed de novo GERD (1.8%) compared with the multi-fire cohort (10.9%) (p = 0.005). Additionally, more patients in the Titan SGS™ Stapler cohort who had GERD prior to the procedure saw resolution of this condition, compared to the multi-fire cohort (25% vs. 10.9%, p = 0.005). Notably, the improvements in GERD outcomes linked to the Titan SGS™ Stapler were achieved without a significant difference in weight loss at 1 year between the two cohorts (multiple-fire: 22.4% ± 0.7%, single-fire: 22.0% ± 1.7%, p = 0.8).*

    "The Titan SGS™ Stapler was developed to enable more consistent and symmetrical sleeve anatomy because we believe that sleeve shape significantly contributes to sleeve gastrectomy efficacy and safety outcomes," said James Ferguson, President and General Manager, Surgical, at Teleflex. "The study's authors hypothesize that the improved GERD outcomes reported in the Titan SGS™ Stapler cohort may be because the 23cm single-fire continuous staple line without overlapping staple firings ‘results in less kinking along the sleeve staple line, which prevents inadvertent narrowing'. This suggests that consistent sleeve shape may play a role in reducing GERD."

    In previous retrospective studies, the Titan SGS™ Stapler has been associated with significantly reduced operative times,8 less post-op nausea and vomiting7-8 and the potential for increased operational efficiencies and significant reductions in LOS and readmissions.4,6-10

    For more information about the Titan SGS™ Stapler or to learn more about the Titan Sleeve™ Technique, visit standardbariatrics.com. Learn about the exciting innovation behind the Titan SGS™ Stapler at: Innovation Story.

    About Teleflex

    As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

    Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

    At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

    Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

    Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, Titan SGS, Titan Sleeve, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

    Dr. Morton and Dr. Ringold, two of the authors of the study, are paid consultants of Teleflex Incorporated.

    *The Titan SGS™ Stapler is intended for longitudinal transection and resection of gastric tissue for sleeve gastrectomy pouch creation. The Titan SGS™ Stapler is one of several instruments used by surgeons during sleeve gastrectomy procedures and has been cleared by FDA based on clinical studies and other data establishing its performance for this purpose. The Titan SGS™ Stapler is not indicated for weight loss.

    © 2025 Teleflex Incorporated. All rights reserved. MC-010771

    References

    _______________

    1Ying L, Rutledge R, Butensky S, et al. Does stapling platform influence robotic sleeve gastrectomy postoperative outcomes?. Obes Surg. 2025; doi: 10.1007/s11695-025-07855-z.

    2 Angrisani L, Santonicola A, Iovino P, et al. Bariatric Surgery Worldwide 2013. Obes Surg. 2015;25:1822–1832. doi: 10.1007/s11695-015-1657-z.

    3 Masood M, Low DE, Deal SB, Kozarek RA. Current management and treatment paradigms of gastroesophageal reflux disease following sleeve gastrectomy. J Clin Med. 2024;13(5):1246. doi: 10.3390/jcm13051246

    4 Thompson J, Dhar V, Hanseman D, et al. Anatomy-based laparoscopic sleeve gastrectomy reduces gastroesophageal reflux disease compared to laparoscopic sleeve gastrectomy with bougie. Surgery for Obesity and Related Diseases, 2017;13(10). doi: 10.1016/j.soard.2017.09.242.

    5 Toro, J., Lin, E., Patel, A., et al. Association of Radiographic Morphology with Early Gastroesophageal Reflux Disease and Satiety Control after Sleeve Gastrectomy. Journal of the American College of Surgeons, 2014;219(3), 430–438. doi: 10.1016/j.jamcollsurg.2014.02.036

    6 U.S. Food and Drug Administration. 510(k) Premarket Notification: K210278. Published April 28, 2021.

    7 Standard Bariatrics, Inc. Multisite comparison of Titan SGS to existing surgical staplers in sleeve gastrectomy; 2022. Qualitee 360 Report. Unpublished raw data. Retrieved from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database.

    8 Fritz GD, Sharrak A, Aubrey J, et al. Perioperative outcomes using single-fire stapler. Obes Surg. 2024;34(9):3553-3560. doi:10.1007/s11695-024-07357-4.

    9 Salyer CE, Thompson J, Hoffman A, et al. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surg Endosc. 2021;35(7):4016-4021. doi:10.1007/s00464-020-07858-0.

    10 Varban OA, Niemann A, Stricklen A, et al. Far from Standardized: Using Surgical Videos to Identify Variation in Technique for Laparoscopic Sleeve Gastrectomy. J Laparoendosc Adv Surg Tech A.2017;27(8):761–767. doi:10.1089/lap.2017.0184.

    Contacts:

    Teleflex

    Lawrence Keusch

    Vice President, Investor Relations and Strategy Development

    [email protected]

    610-948-2836



    Primary Logo

    Get the next $TFX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/1/2024$205.00 → $245.00Neutral → Overweight
    Piper Sandler
    12/4/2023$261.00Equal-Weight → Overweight
    Morgan Stanley
    6/21/2023Buy → Hold
    Needham
    More analyst ratings

    $TFX
    Financials

    Live finance-specific insights

    See more
    • Teleflex Announces Quarterly Dividend

      WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi

      5/12/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook

      WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.21 in the prior year period 2025 guidance summary Raising GAAP revenue growth guidance range to 1.28% to 2.28% Maintaining adjusted constant currency revenue growth guidan

      5/1/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Announces First Quarter 2025 Earnings Conference Call Information

      WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all ot

      4/17/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/14/24 1:28:29 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/8/24 10:29:30 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      2/14/24 10:04:36 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TFX
    Leadership Updates

    Live Leadership Updates

    See more

    $TFX
    SEC Filings

    See more

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Director Duncan Candace H exercised 4,833 shares at a strike of $123.04 and covered exercise/tax liability with 4,705 shares, increasing direct ownership by 3% to 4,856 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/7/25 6:38:49 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Executive Vice President & CFO Powell Thomas E covered exercise/tax liability with 468 shares and returned 655 shares to the company, decreasing direct ownership by 5% to 20,812 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      4/3/25 4:08:13 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Corp. VP & CAO Deren John was granted 2,676 shares, increasing direct ownership by 140% to 4,588 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      3/6/25 6:13:45 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

      WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

      2/27/25 6:36:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Teleflex Incorporated

      10-Q - TELEFLEX INC (0000096943) (Filer)

      5/1/25 11:49:55 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TELEFLEX INC (0000096943) (Filer)

      5/1/25 7:00:52 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Teleflex Incorporated

      DEFA14A - TELEFLEX INC (0000096943) (Filer)

      3/28/25 4:19:09 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by BofA Securities with a new price target

      BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously

      3/4/25 7:44:32 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously

      2/28/25 7:34:55 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by Raymond James

      Raymond James downgraded Teleflex from Outperform to Mkt Perform

      2/28/25 7:34:03 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy

      Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the publication of a new retrospective analysis of clinical data associating the use of the Titan SGS™ Stapler with reduced rates of post-operative GERD following robotic-assisted laparoscopic sleeve gastrectomy (LSG) compared

      5/13/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Announces Quarterly Dividend

      WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi

      5/12/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook

      WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.21 in the prior year period 2025 guidance summary Raising GAAP revenue growth guidance range to 1.28% to 2.28% Maintaining adjusted constant currency revenue growth guidan

      5/1/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care